文献速递免疫规划

BBIBP-CorV、Gam-COVID-Vac及Gam-COVID-Vac/mRNA-1273异源COVID-19疫苗接种方案针对不同SARS-CoV-2变异株的T细胞免疫记忆应答评价

Evaluation of T cell immune memory response after BBIBP-CorV, gam-COVID-Vac, and heterologous gam-COVID-Vac /mRNA-1273 COVID-19 vaccination schemes against different SARS-CoV-2 variants.
PubMed 文献 · Vaccine · 2025-07-23

研究纳入60名受试者,均分为BBIBP-CorV、Gam-COVID-Vac和Gam-COVID-Vac/mRNA-1273三组,用活化诱导标志物法检测针对 ancestral 野生型、Gamma和Omicron变异株的T细胞应答,并用CMIA检测血清IgG。Gam-COVID-Vac/mRNA-1273组体液应答显著更高(p<0.001),三组T细胞应答一致;三种方案针对野生型的CD8+应答更强,BBIBP-CorV和Gam-COVID-Vac组对野生型应答者更多,异源组对Omicron应答者比例更高。

要点

  • Gam-COVID-Vac/mRNA-1273异源方案体液应答显著更高(p<0.001),三组T细胞应答一致。
  • 三种方案均诱导针对野生型病毒更强的CD8+应答。
  • BBIBP-CorV和Gam-COVID-Vac组对野生型应答者更多,异源组对Omicron应答者比例更高。

核心结论

  • 三种疫苗方案均可诱导针对野生型、Gamma和Omicron变异株的体液和细胞免疫应答,记忆CD4+和CD8+ T细胞应答仍具保护性,异源方案可能对新兴变异株诱导更强的T细胞应答。

研究设计与样本

  • 研究纳入60名受试者,均匀分布于BBIBP-CorV、Gam-COVID-Vac和Gam-COVID-Vac/mRNA-1273三组;用CMIA(Abbott Diagnostics)检测血清IgG抗体水平,用活化诱导标志物法评估针对野生型、Gamma和Omicron的T细胞应答。

主要发现

  • 受试者中位年龄48岁(IQR:34-56),女性占58.3%(n=35),17人(28.3%)有既往确诊COVID-19感染。
  • Gam-COVID-Vac/mRNA-1273方案诱导体液应答显著更高(p<0.001),但三种疫苗平台在三种刺激下T细胞应答一致。
  • 三种方案均诱导针对野生型病毒更强的CD8+应答;BBIBP-CorV和Gam-COVID-Vac组对野生型的应答者更多,Gam-COVID-Vac/mRNA-1273组对Omicron的应答者比例更高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The adaptive immune response plays a crucial role in resolution of viral infections; however, there is limited data on the T cell response to SARS-CoV-2 vaccines such as BBIBP-CorV, Gam-COVID-Vac, and especially for the heterologous combination Gam-COVID-Vac/mRNA-1273 scheme. Furthermore, emerging variants may compromise the adaptive immune response established in the population. OBJECTIVE: To evaluate the T cell immune response induced by the BBIBP-CorV, Gam-COVID-Vac and Gam-COVID-Vac/mRNA-1273, against the ancestral wild type (WT) virus and the Gamma and Omicron variants. METHODS: Serum levels of IgG antibodies were assessed by CMIA (Abbott Diagnostics, Abbott Park, Illinois). T cell responses against WT virus, Gamma and Omicron were evaluated through an activation-induced marker assay. Sixty individuals, evenly distributed across the BBIBP-CorV, Gam-COVID-Vac, and Gam-COVID-Vac/mRNA-1273 groups, were included. RESULTS: The median age of participants was 48 years (IQR: 34-56), with 58.3 % (n = 35) being female. Seventeen (28.3 %) individuals had a prior confirmed COVID-19 infection. Gam-COVID-Vac/mRNA-1273 scheme elicited significantly higher humoral responses (p < 0.001). However, the three vaccination platforms showed consistent T cell responses across the three stimuli tested. Particularly, all three schemes induced stronger CD8+ responses against the WT virus. In addition, more responders to WT were observed in the BBIBP-CorV and Gam-COVID-Vac groups, while the Gam-COVID-Vac/mRNA-1273 group showed a greater proportion of responders to Omicron. CONCLUSION: This study provides new data on effective humoral and cellular immune responses against the ancestral WT virus as well as the Gamma and Omicron variants. Moreover, memory CD4+ and CD8+ T cell responses remain protective, and the heterologous scheme may elicit stronger T cell responses against emerging variants.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Pereson MJ, Badano MN, Sabbione F, et al. Evaluation of T cell immune memory response after BBIBP-CorV, gam-COVID-Vac, and heterologous gam-COVID-Vac /mRNA-1273 COVID-19 vaccination schemes against different SARS-CoV-2 variants. Vaccine. 2025. PMID: 40706509. doi:10.1016/j.vaccine.2025.127526

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。